Prostate Cancer Foundation posted the following on X:
“T-cell engager therapies act like a bridge, connecting immune cells to cancer cells. Half of patients in the early trial of a STEAP-1-targeting agent had PSA50 response. Phase 3 trials now at multiple centers.
Neeraj Agarwal explains in our latest webinar.”